In Vitro Fertilisation (Ivf)
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
World Fertility and Family Planning 2020: Highlights (ST/ESA/SER.A/440)
World Fertility and Family Planning 2020 Highlights ST/ESA/SER.A/440 Department of Economic and Social Affairs Population Division World Fertility and Family Planning 2020 Highlights United Nations New York, 2020 The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. The Population Division of the Department of Economic and Social Affairs provides the international community with timely and accessible population data and analysis of population trends and development outcomes for all countries and areas of the world. To this end, the Division undertakes regular studies of population size and characteristics and of all three components of population change (fertility, mortality and migration). Founded in 1946, the Population Division provides substantive support on population and development issues to the United Nations General Assembly, the Economic and Social Council and the Commission on Population and Development. It also leads or participates in various interagency coordination mechanisms of the United Nations system. -
20. Riesgos Y Complicaciones En FIV-ICSI
01 serono 1-6 OK:Maquetación 1 8/3/07 12:14 Página 223 20. Riesgos y complicaciones en FIV-ICSI RIESGOS DERIVADOS DEL TRATAMIENTO HORMONAL Estimulación ovárica y riesgo de cáncer La medicación para estimular la ovulación se utiliza desde hace unos cuarenta años para tratar la infertilidad. En los últimos veinte años, diferentes estudios empiezan a cuestio- nar la seguridad de estos fármacos y su relación con distintos tipos de cáncer. Ayhan y cols. en una revisión en el año 2004, concluyen que se necesitan estudios prospectivos, multicéntricos y durante largos periodos de tiempo para determinar la relación entre el uso de los fármacos para estimular la ovulación y el riesgo de cáncer(1). En el año 2000, Klip et al. realizan una revisión desde 1966 a 1999 donde se analiza la relación entre el uso de fármacos de estimulación ovárica y el riesgo de cáncer de ova- rio, mama, endometrio, tiroides y melanoma. Aunque se sugiere una relación entre el uso de los fármacos y el riesgo de cáncer, no existen estudios epidemiológicos que lo demues- tren(2). Más tarde, Kashyap et al. 2004, en su metaanálisis, demuestran una tendencia hacia un efecto beneficioso de las técnicas de reproducción asistida, ya que suelen fina- lizar en embarazo, que es un factor protector contra el cáncer de ovario(3). Sin embargo, Ness et al., 2002, publicaron un metaanálisis(4), en el que encontraban un ligero aumento de riesgo de neoplasia borderline en pacientes que habían sido expues- tas a tratamientos de infertilidad, cuando se comparaba con la población normal, pero Mosgaard demostró que ello es debido en parte a la propia infertilidad(5). -
The ART of Assisted Reproductive Technology
Infertility • THEME The ART of assisted reproductive technology BACKGROUND One in six Australian couples of The Australian Institute of Health and Welfare's reproductive age experience difficulties in National Perinatal Statistical Unit's annual report Jeffrey Persson, conceiving a child. Once a couple has been Assisted reproductive technology in Australia and New MD, FRANZCOG, CREI, is Clinical appropriately assessed, assisted reproductive Zealand 2002, shows that babies born in 2002 using Director (City), technology (ART) techniques can be used to assisted reproductive technology (ART) had longer IVFAustralia. overcome problems with ovulation, tubal patency, gestational ages, higher birth weights and fewer peri- [email protected] male fertility or unexplained infertility. natal deaths than their counterparts of 2 years OBJECTIVE This article discusses the range of previously.1 ART techniques available to subfertile couples. This is the first year national data have been avail- able on the age of women (and their partners) using DISCUSSION Intracytoplasmic sperm injection is now the most common form of ART used in ART. The average age of women undergoing treat- Australia, being used in almost half of all fresh ment in 2002 was 35.2 years, and the average cycles, with in vitro fertilisation being used in age of partners was 37.6 years.1 Age remains the approximately one-third of all fresh cycles. most significant issue affecting a couple's chance of conceiving and carrying a pregnancy to full term. Women need to understand the impact age has on their chance of becoming pregnant. Once a couple has been assessed and investigations suggest subfer- tility, the treatment options depend on the underlying cause (Table 1). -
Knowledge, Intentions, and Beliefs About Fertility and Assisted
KNOWLEDGE, INTENTIONS, AND BELIEFS ABOUT FERTILITY AND ASSISTED REPRODUCTIVE TECHNOLOGY AMONG ILLINOIS COLLEGE STUDENTS by Akilah Morris Smith B.S., Illinois State University, 2006 M.S., Illinois State University, 2008 A Dissertation Submitted in Partial Fulfillment of the Requirements for the Doctorate in Philosophy Department of Public Health and Recreation Professions in the College of Education Southern Illinois University Carbondale Spring 2018 Copyright by Akilah Morris Smith, 2018 All Rights Reserved i DEDICATION I want to thank My Heavenly Father for all his guidance, support and love during this time. Thanks for challenging and blessing me. I have learned that you are authentic and real in my life. I also want to thank my mother and father Olivia and Arthur Morris for loving and supporting me unconditionally through this time. I am grateful for the best brother in the world Oheni Morris, thank you for your light heartedness, positivity and love. Thanks to my husband Wayon Smith III, son Wayon Smith IV (KJ) and in laws Mr. and Mrs. Wayon Simth Jr. and Mrs. Faye Freeman Smith for helping me during graduate school. ii ACKNOWLEDGEMENTS Thanks to my extended family and friends who listened and added valuable input during this season of my life. Special thanks to Dr. Ogletree, Dr. Wallace, Dr. Melonie Ewing, Dr. Shelby Caffey, and Dr. Diehr for their commitment in seeing me through this process. iii AN ABSTRACT OF THE DISSERTATION OF AKILAH MORRIS SMITH, for the Doctor of Philosophy degree in Public Health, presented on April 11th 2018, at Southern Illinois University Carbondale. TITLE: KNOWLEDGE, INTENTIONS, AND BELIEFS ABOUT FERTILITY AND ASSISTED REPRODUCTIVE TECHNOLOGY AMONG ILLINOIS COLLEGE STUDENTS MAJOR PROFESSOR: Roberta Ogletree H.S.D and Juliane P. -
Understanding Your Menstrual Cycle If You're Trying to Conceive
IS MY PERIOD NORMAL? Understanding Your Menstrual Cycle If You’re Trying to Conceive More than 70% 11% 95% of women have or more of of U.S. women start irregular menstrual American women their periods by cycles as menopause suffer from age 16. approaches. endometriosis.1 10% 12% of U.S. women are of women have affected by PCOS trouble getting or (polycystic ovary staying pregnant.3 syndrome).2 Fortunately, your menstrual cycle can tell you a lot about your fertility if you know what to look for. TYPES OF MENSTRUAL CYCLES Only 15% of About Normal = women have 30% of women are fertile only during 21 to 35 days the “perfect” the “normal” fertility 28-day cycle. window—between days 10 and 17 of the menstrual cycle. Day 1 Period starts (aka menses) 27 28 1 2 26 3 25 4 24 5 Day 15-28 23 6 Day 2-14 Luteal phase; Follicular phase; progesterone** 22 WHAT’S NORMAL? 7 FSH released, (follicle- uterine lining 21 8 stimulating matures Give or take a few days, hormone) and a normal cycle looks like this: estrogen released, 20 9 ovulation* begins 19 10 18 11 17 12 16 15 14 13 *ovulation: the process of an ovum (egg) being released from the ovary; occurs 10-14 days before menses. **progesterone: a steroid hormone that tells the uterus to prepare for pregnancy At least 30% of women have an “irregular” cycle either short, long or inconsistent. Short = Long = < 21 days > 35 days May be a sign of: May be a sign of: Hormonal imbalance Hormonal imbalance Ovaries with fewer eggs Lack of ovulation Approach of menopause Other fertility issues Reduced fertility4 Increased risk of miscarriage SIGNS TO WATCH FOR Your menstrual cycle provides valuable clues about your body’s reproductive health. -
Should Men Worry About Dry Orgasms? a Dry Orgasm?
The Online Resource for Sexual Health Patient Education SexHealthMatters.org is brought to you by the Sexual Medicine Society of North America, Inc. Should Men Worry About Dry Orgasms? A dry orgasm? For men, it sounds like a contradiction, doesn’t it? Men ejaculate semen at orgasm. Doesn’t that make orgasms, by definition, wet? The answer is: Not all the time. Some men reach orgasm – and feel great pleasure from it – but do not ejaculate any semen at all. Or, they might ejaculate a very small amount. This is what we mean by “dry orgasm.” While they might seem a bit unusual, dry orgasms are usually nothing to worry about. They can be a challenge for couples who would like to conceive, but they generally not a health risk. What causes dry orgasms? Men may have dry orgasms for a variety of reasons. Younger men with short refractory periods might have them occasionally. The refractory period is a period of time after orgasm during which a man’s body recovers and doesn’t respond to sexual stimulation. These intervals often don’t last long in younger men. In fact, it can be just minutes before a man is “ready to go” again. And he might climax several times during one sexual encounter. Eventually, however, the well runs dry. A man has a limited amount of semen to ejaculate and if he keeps going, that supply will be depleted. It’s not a cause for worry, though. In a day or two, the man’s body will produce semen to replace what has been ejaculated and he’ll be back to a full supply. -
Thinking About Having a Baby? Most People Want to Become Parents One Day
Thinking about having a baby? Most people want to become parents one day Fertility is the ability to have a baby. Many things can affect women’s and men’s fertility, including their age, when they have sex, how healthy they are, and whether they have any medical conditions. 5 ways to improve your chance of getting pregnant and having a healthy baby 1. Age If you have a choice, trying for a baby sooner rather than later improves your Age is the most important factor when it comes to fertility, as fertility declines with age. chance of pregnancy. Women younger than 35 and men younger than 40 have a better chance of having a child than 2. Timing of sex people who are older. This is true for natural pregnancies and for pregnancies conceived Having sex on the days when a woman is fertile, through assisted reproductive treatments such increases the chance of pregnancy. It’s all about as IVF (in-vitro fertilisation). timing! After having sex, sperm live for about five days. Eggs can only be fertilised for about one • Women younger than 30 have about a 20 day after ovulation (when an egg is released per cent chance of getting pregnant naturally from the ovary). each month. By age 40, the chance of pregnancy is about five per cent each month. The best time to have sex to become pregnant is during the ‘fertile window’, which is the day • It takes longer to conceive for women whose of ovulation and the five days before that. A male partners are older than 40. -
COVID-19 Vaccination and Reproduction: Pregnancy, Lactation, Fertility, and Family
COVID-19 Vaccination and Reproduction: Pregnancy, Lactation, Fertility, and Family Sarah L. Berga, MD Professor and Chair Department of Obstetrics and Gynecology Jacobs School of Medicine and Biomedical Sciences | UB SUNY Medical Director Obstetrics and Gynecology and Women’s Health Program Development Oishei Children’s Hospital | Kaleida Health Disclosures: Sarah L Berga MD August 2021 CONSULTING: Ferring Pharmaceuticals SW Reproductive Health Advisory Board, 10.25.19, Denver, CO ClearBlue Medical Advisory Board, 11.20.19, Washington DC EDITORIAL BOARDS & POSITIONS: American Journal of Obstetrics and Gynecology, Advisory Board: 2003-present (Gratis) Human Reproduction Update, Associate Editor, 2017 to 2020 (gratis) International Society for Gynecological Endocrinology, Executive Committee Member: 2004-present (Gratis) Journal of Obstetrics and Gynecology Canada, International Editorial Board: 2017-present (Gratis) Mayo Clinic Proceedings, Editorial Board: 2019-present (Gratis) Menopause, Editorial Board: 1999-present (Gratis) UpToDate, Peer Review Board: 2005-present SERVICE: Member, Board of Trustees, Salem Academy and College, Salem, NC: 2018-present (Gratis) COVID-19 Vaccination and Reproduction: Pregnancy, Lactation, Fertility, and Family LEARNING OBJECTIVES • Understand the risks and benefits of COVID-19 vs COVID-19 vaccination in: • Men and women with infertility or fertility concerns • Pregnant women • Lactating women • Family members COVID-19 Vaccination and Reproduction: Pregnancy, Lactation, Fertility, and Family • Vaccination -
ASCO Answers: Your Fertility and Cancer Treatment
Your Fertility and Cancer Treatment What is fertility and infertility? Fertility is the physical ability to have a child. It means you can become pregnant and give birth to a baby, or you are able to fertilize an egg with sperm. Infertility means you are not physically able to have a child. A person with infertility is not able to become pregnant, maintain a pregnancy, or fertilize an egg. Could cancer treatment affect my fertility? Often, yes. Infertility has many different causes, including some types of cancer treatment. If you want to have a child after cancer treatment, talk with your oncologist about your fertility before starting cancer treatment. Cancer treatment can cause infertility by damaging or destroying eggs or sperm and by damaging or removing organs involved in creating or carrying an unborn baby, such as the testicles, ovaries, or uterus. Which cancer treatments can cause infertility? Chemotherapy is the most common cancer treatment that may affect a person’s fertility. Ask about targeted therapy and immunotherapy drugs, too. Some medications, especially drugs called “alkylating agents,” have a higher risk of causing infertility. Cancer medications that affect fertility can be used for many different types of cancer. Radiation therapy and surgery affecting certain areas of the body can also make you infertile. For example, removing the uterus or ovaries will cause infertility. If a treatment causes early menopause, the time when ovaries stop producing estrogen, it may cause infertility. Before treatment, ask your health care provider if any part of your cancer treatment plan could affect your fertility. Can I plan ahead to have children after cancer treatment? In many cases, yes. -
Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009†
Human Reproduction, Vol.24, No.11 pp. 2683–2687, 2009 Advanced Access publication on October 4, 2009 doi:10.1093/humrep/dep343 SIMULTANEOUS PUBLICATION Infertility The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) Revised Glossary on ART Terminology, 2009† F. Zegers-Hochschild1,9, G.D. Adamson2, J. de Mouzon3, O. Ishihara4, R. Mansour5, K. Nygren6, E. Sullivan7, and S. van der Poel8 on behalf of ICMART and WHO 1Unit of Reproductive Medicine, Clinicas las Condes, Santiago, Chile 2Fertility Physicians of Northern California, Palo Alto and San Jose, California, USA 3INSERM U822, Hoˆpital de Biceˆtre, Le Kremlin Biceˆtre Cedex, Paris, France 4Saitama Medical University Hospital, Moroyama, Saitana 350-0495, JAPAN 53 Rd 161 Maadi, Cairo 11431, Egypt 6IVF Unit, Sophiahemmet Hospital, Stockholm, Sweden 7Perinatal and Reproductive Epidemiology and Research Unit, School Women’s and Children’s Health, University of New South Wales, Sydney, Australia 8Department of Reproductive Health and Research, and the Special Program of Research, Development and Research Training in Human Reproduction, World Health Organization, Geneva, Switzerland 9Correspondence address: Unit of Reproductive Medicine, Clinica las Condes, Lo Fontecilla, 441, Santiago, Chile. Fax: 56-2-6108167, E-mail: [email protected] background: Many definitions used in medically assisted reproduction (MAR) vary in different settings, making it difficult to standardize and compare procedures in different countries and regions. With the expansion of infertility interventions worldwide, including lower resource settings, the importance and value of a common nomenclature is critical. The objective is to develop an internationally accepted and continually updated set of definitions, which would be utilized to standardize and harmonize international data collection, and to assist in monitoring the availability, efficacy, and safety of assisted reproductive technology (ART) being practiced worldwide. -
Scientific Programme 30 April
Scientific Programme 30 April - 3 May 2014 Adding pieces to the puzzle of endometriosis Contents 16.00 to 18.30 Sponsors 4 Welcome 5 Partner organisations 8 WES and committees 9 Venue plan 10 At a glance programme 12 Pre-congress courses Wednesday 14 Opening ceremony 19 Programme Thursday 20 Programme Friday 24 Programme Saturday 28 Closing ceremony 31 Exhibitor / poster floor plan 32 Sponsor profiles 33 List of presenters 36 Local information 42 The organisers of WCE2014 would like to thank our generous sponsors Diamond Gold Ruby Silver Bronze Supported by 4 Welcome Dear Colleagues and Friends, Welcome to São Paulo and to the 12th World Congress on Endometriosis. The theme of WCE2014, “Adding pieces to the puzzle of endometriosis”, has been chosen because we Maurício Simões Abrão, are currently experiencing a rapid advancement of new technologies for the diagnosis and management WCE2014 President of endometriosis and, with that, improvements in our understanding of the disease. At the heart of every congress is the scientific programme, which keeps the momentum of our advancements in endometriosis alive through a robust exchange of ideas among the experts and learners in the field. We have received more than 500 outstanding abstracts from the international community, and have put together an extensive and in-depth programme featuring more than 150 speakers and close to 300 poster presentations spanning almost every topic you can imagine that has relevance to endometriosis. This is truly the world event on endometriosis and I welcome each and every one of you to São Paulo to be part of this clinical and scientific extravaganza! For me it is an exciting time to welcome you to São Paulo, one of the top international capitals for gastronomy, architecture and design, cultural heritage and music. -
In Vitro Fertilisation and Embryo Research
Briefing Note INFORMATION FOR MEMBERS FROM THE 6 Parliamentary Office of Science and Technology November 1989 Figure 1.. Conceptus after 15 days In Vitro Fertilisation and Embryo Research Actual size Following the Warnock Report of 1984 and the 1987 White Paper, the Government has introduced the Human Fertilisation and Embryology Bill con taining provisions on research involving human embryos. Parliament is asked to decide between two options set out in Section 11 of the Bill which determine whether the Human Fertilisation and Embryology Authority(HFEA) is empowered to grant licences for research involving human embryos less than 14 days old. This question involves substantial ethical and religious considerations. An understanding of scientific aspects of human fertilisation and embryology may assist Parliamentarians to come to grips with these considerations. Some of the relevant science and technology is de scribed in this note. it is argued that this should not be such as to prevent the benefits to others which research may provide. THE STATUS OF THE EARLY EMBRYO Science alone cannot resolve this question, but a clearer understanding of the early developmental process of An important issue relates to the status afforded the the fertilised egg may provide illumination to allow in fertilised egg and the early (pre-14 day) embryo or dividuals to reach their own decision. conceptus1. Some argue that these should have the status of a human being from the moment of fertilisa Early Human Development tion, since the fusion of egg and sperm produces a unique genetic combination which, if it develops nor After the egg has been fertilised, it divides into two mally, will develop into a child.